

Effects of Diet on Gut Microbiota Profile and the Implications for Health and Disease

Yuan-Kun LEE¹

¹Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, 117597 Singapore

Received August 20, 2012; Accepted September 10, 2012

Gut microbes are present in large concentrations on the human intestinal mucosal surface and play important roles in health and disease of the host. Numerous groups of gut microbes are associated with immunological and metabolic diseases and in maintaining health status of the host. Among these health- and disease-associated gut microbes, *Bacteroides*, *Clostridium* and *Bifidobacterium* appear regularly in the list. Scientific and clinical evidence available to date indicates that diet is a major driving factor for the establishment of the gut microbiome. Slow digestible carbohydrates (human milk glycan, inulin and fructooligosaccharide), insoluble complex carbohydrates and protein diets favor the growth of *Bacteroides*, *Clostridium* and *Bifidobacterium*. Fat on the other hand suppresses the number of *Bacteroides*, *Clostridium* and *Bifidobacterium*; whereas polyphenols in general suppress *Bacteroides* and *Clostridium* but enhance the *Bifidobacterium*. The implication is that dietary habits could be a major determinant of health and disease susceptibility. Dietary strategies could be an effective means of potentially inducing changes in intestinal microbiota and are certainly achievable, thus facilitating correction of intestinal microbiome aberrations or imbalances to improve our health. Most of the physiological and functional interactions between individual dietary components and the concoction of foods in a meal and gut microbiota have not yet been well studied. A concerted effort is required to acquire better understanding of their interaction in order to rationally maintain our intestinal microbiome homeostasis and general health through dietary intervention.

Key words: gut microbes, microbiome, microbiota profile, diet

GUT MICROBES AND HEALTH

Gut microbes play important roles in health and disease of the host for the obvious reasons that they are present in large concentrations, closely associated with the host mucosal surface and interact with the host.

It has been widely demonstrated in animal and clinical studies that gut microbiota are involved in maturation and regulation of host immunity and gut functions. Capsular antigen of the human commensal *Bacteroides fragilis* triggers T cell-dependent immune responses that can affect both the development and homeostasis of the host immune system [1–3]. Colonization of the intestinal tract by *Lactobacillus* and *Bifidobacterium* exerts a barrier effect and protects the host against pathogens [4–6]. *Escherichia coli*, *Klebsiella pneumonia* and *Streptococcus viridans* on the other hand significantly increase intestinal permeability. An increase in permeability can lead to inappropriate immune responses, resulting in diseases

like Crohn's disease [7], Celiac disease and associated type 1 diabetes mellitus [8].

It has been reported that disruption of the microbiome balance can result in overgrowth of Gram-negative enteric bacteria such as *Pseudomonas* and *Staphylococcus aureus* and a lower level of *Bifidobacterium*, *Eubacterium rectale/Clostridium coccoides* group and *Bacteroides*-like MIB, resulting in a higher incidence of systemic infection [9] and metabolic disorder [10].

Certain intestinal bacteria such as *Bacteroides*, *Enterobacteriaceae* and *Clostridium* are able to produce mutagens in the presence of dietary precursors, through the actions of β -glucuronidase and nitroreductase [11]. Free radical-producing *Enterococcus faecalis*, has a positive correlation with human adenomas [12].

Additionally, certain lactic acid bacteria, such as *Lactobacillus rhamnosus* and *Lactobacillus acidophilus*, produce bactericidal substances such as bacteriocins, lactic acid and acetic acid [13]. Lower intestinal pH also increases inhibitory activities of other organic acids. Bacterial metabolites such as hydrogen peroxide can also be cytotoxic to other bacteria [5, 14]. *Bifidobacterium* produces antimicrobial agents that inhibit Gram-positive and Gram-negative organisms [15].

Bacterial fermentation of dietary fiber and slowly

Corresponding Author. Mailing address: Yuan-Kun Lee, Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, 117597 Singapore. Phone: +65-65163284, Fax: +65-67766872. E-mail: micleeyk@nus.edu.sg

digestible carbohydrates forms a range of bacterial metabolites, including short-chain fatty acids (SCFAs), typically acetate, propionate and butyrate. These represent additional energy sources for the host, which would otherwise not be available. Acetate is mainly metabolized in the peripheral tissues and is lipogenic, whereas propionate is transported to the liver and is gluconeogenic. Butyrate is the preferred energy source for the colonocytes and has a role in regulating host gene expression [16, 17].

Methanogens comprise up to 10% of all anaerobes in the colons of healthy adults [18–20]. The most common methanogenic archaeon found in the gut is *Methanobrevibacter smithii*, which can reduce CO₂ with H₂ to methane, allowing an increase in transformation of nutrients into calories [21]. The colonization of *Methanobrevibacter* in anorexia nervosa patients has been suggested to be an adaptive attempt towards optimization of food transformation in very low calorie diet intake by these patients. The hosts, however, do pay a price in harboring *Methanobrevibacter*, as it is related to constipation and diverticulosis [22, 23].

The two most abundant bacterial phyla found in healthy individuals are the Bacteroidetes and Firmicutes [24, 25]. The relative abundance of the two phyla in healthy adults appears to be relatively constant, although they do not always comprise the same species. This suggests multiple representatives of the functional groups [26]. The existence of dominant groups of bacteria presumably acts to conserve the metabolic functions essential to gut health, and indeed, a functional gene core has been identified in the gut metagenome [27]. Overall, a balanced gut microbiota composition confers benefits to the host, while microbial imbalances are associated with metabolic and immune-mediated disorders (as summarized in Table 1).

It is interesting to note that *Bacteroides* among the Bacteroidetes, and lactic acid bacteria (*Bifidobacterium*) and *Clostridium* among the Firmicutes consistently appear in diseases involving intestinal microbiome aberrations (in Table 1), and their aberrations could be either higher or lower in abundance. These again support the notion that microbiome homeostasis contributes to gut health and disease.

There is increasing clinical evidence demonstrating that these gut microbiota-linked diseases could be prevented and reverted through microbial (probiotic) intervention. Probiotics are live microorganisms that when administered in adequate amounts confer a health benefit in the host [55]. In clinical studies providing a selected *Bifidobacterium* or *Lactobacillus* to mothers with a family history of atopic diseases 2–4 weeks before delivery and to the newborn for 6 months, the incidences

of atopic diseases was successfully reduced by half in the infants, and the beneficial effect was still evident after seven years [56, 57]. *Lactobacillus*, *Bifidobacterium*, *Streptococcus* and *Escherichia coli* showed a protective effect against inflammatory bowel disease in human studies [58, 59]. *Lactobacillus* and *Bifidobacterium* improve the clinical conditions in patients with irritable bowel syndrome [60]. In a study on mutagenicity of beef consumption, *Lactobacillus casei* intake was shown to reduce mutagenicity in urine. This was attributed to reduction in the population of pro-mutagen-forming intestinal bacteria [61]. In patients who underwent surgical treatment for superficial bladder cancer, intake of *Lactobacillus* prolonged the recurrence-free period [62, 63]. These studies suggest that intestinal microbiota are directly involved in the causation of these diseases, and demonstrate the prospect of balancing gut microbiota for prevention and treatment of these diseases.

Consumption of *Lactobacillus*-fermented milk resulted in an increase in *Lactobacillus* and *Bifidobacterium* counts accompanied by a decrease in *Clostridium* counts [64]. Other fermented foods, such as Japanese natto and miso, also affect intestinal microbiota. Consumption of these foods resulted in increased levels of *Bacillus* and *Bifidobacterium* and decreased levels of *Enterobacteriaceae* and *Clostridium* [65].

The probiotic approach, though effective in amending the gut microbiome, is a reactive approach nonetheless, as the gut environment of a diseased individual probably favors the proliferation and establishment of aberrant disease-causing microbes. Maintaining intestinal microbiome homeostasis is arguably a desirable approach in disease prevention. To achieve intestinal microbiome homeostasis, it is necessary to understand factors that influence microbiome composition.

The composition of the gut microbiota is influenced by endogenous and external factors, such as microbes acquired at birth, diet, host physiology, drug intake and disease [66]. Of these factors, the diet is considered a major driver for changes in gut microbiota diversity, as it provides nutrition and alters the microenvironment for microbes. It could be safely assumed that the distinct differences in microbiota of the adult and infant types are the responses to the host physiological stage and to their different diets. Dietary strategies could be an effective means of potentially inducing changes in intestinal microbiota and are certainly achievable, thus facilitating correction of intestinal microbiome aberrations or imbalances to improve our health.

Table 1. Examples of aberrations in the gut microbiota linked to diseases

Gut bacteria	Level change	Health effect	References
Immunological dysfunction			
Type 2 diabetes			
<i>Bacteroides</i> , <i>Proteobacteria</i>	High		[28]
<i>Firmicutes</i> , <i>Clostridium</i> , <i>Bifidobacterium</i>	Low		[28, 29]
Inflammatory bowel disease (IBD)			
Sulphate-reducing bacteria, <i>Escherichia coli</i>	High		[30–32]
<i>Clostridium</i> IXa, IV (<i>F. prausnitzii</i>) groups, <i>Bacteroides</i> , <i>Bifidobacterium</i>	Low		[30, 32]
Ulcerative colitis pouchitis (a form of IBD)			
<i>Clostridium</i> , <i>Eubacterium</i> , <i>Firmicutes</i> , <i>Verrucomicrobia</i>	High		[33, 34]
<i>Lactobacillus</i> , <i>Streptococcus</i> , <i>Bacteroides</i> , <i>Proteobacteria</i>	Low		[33, 34]
Crohn's disease (a form of IBD)			
<i>Bacteroides vulgatus</i> , <i>Enterobacteriaceae</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumonia</i> and <i>Streptococcus viridans</i>	High		[7, 35–37]
<i>Lactobacillus</i> , <i>Bifidobacterium</i>	Low		[7, 35–37]
Coeliac disease			
<i>Bacteroides-Prevotella</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumonia</i> and <i>Streptococcus viridans</i>	High		[38, 39]
<i>Bifidobacterium</i> , <i>Clostridium histolyticum</i> , <i>C. lituseburense</i> , <i>F. prausnitzii</i>	Low		[38]
Rheumatoid arthritis			
Segmented filamentous bacteria	High		[29]
<i>Bifidobacterium</i> , <i>Bacteroides-Prevotella</i> group, <i>Bacteroides fragilis</i> subgroup, <i>E. rectale-C. coccoides</i> group	Low		[40]
Autism			
<i>Clostridium histolyticum</i> group (<i>Clostridium</i> cluster I & II), <i>Bacteroides</i>	High		[41, 42]
<i>Bifidobacterium</i>	Low		[43]
Obesity/metabolic disorder			
<i>Lactobacillus</i> , <i>Faecalibacterium prausnitzii</i> , <i>Staphylococcus aureus</i> , <i>Methanobrevibacter smithii</i> , <i>Prevotella</i>	High		[20, 44–48]
<i>Bacteroides</i> , Sulphate-reducing bacteria, <i>Bifidobacterium</i>	Low		[44, 47, 49, 50]
Anorexia nervosa			
<i>Methanobrevibacter smithii</i>	High		[44]
Metabolic dysfunction			
Colorectal cancer/ adenomatous polyposis			
<i>B. fragilis</i> , <i>B. thetaiotaomicron</i> , <i>B. ovatus</i> , <i>B. uniformis</i> , <i>Clostridium leptum</i> , <i>C. coccoides</i> subgroups	High		[11, 51–53]
<i>Enterobacteriaceae</i> , <i>Enterococcus faecalis</i>			
<i>Bifidobacterium</i>	Low		[54]

DIETS AFFECTING THE COMPOSITION OF THE GUT MICROBIOME

It was estimated that about 40% of the microbial genes present in each human individual are shared with at least half of the human individuals in the same

geographical cohort [27]. This suggests the existence of a functional core (core microbiome). The functional core may contain shared metabolic functions (e.g., degradation of carbohydrates, production of vitamins) as well as sequential pathways that would, respectively, restrict or expand functional diversity. Several recent

reviews have discussed evolutionary and functional aspects of microbial diversity in the human intestine [67–69]. The aim of this paper was to extend and exploit new insights, so as to provide better understanding of the responsiveness, variability and resilience of the gut microbiome community with regard to dietary intake and host physiology.

Carbohydrates and sugars

Slow digestible oligosaccharides

The most studied dietary components affecting human health and the gut microbiome are the slowly digestible complex carbohydrates, such as oligosaccharides, which are termed prebiotics [70]. They are slowly digestible by human digestive enzymes but fermentable by some gut microbes, thus selectively stimulating the proliferation and/or activity of selected gut bacterial populations.

The first natural slowly digestible oligosaccharides we encounter are the human milk glycans (HMG), which enrich the gut microbiota that are able to metabolize complex carbohydrates [71]. The ability of certain *Bifidobacterium* strains (in particular *B. infantis*) to efficiently use HMG suggests that production of milk oligosaccharides by the mother may be a strategy to ensure the presence of this group of bacteria in the infant gut [72]. The consumption of HMG by *Bacteroides* species [73] suggests that milk glycans may attract different groups of mutually benefiting microbes to the infant intestine. The colonization of *Bacteroides* in our intestinal tract is an example of the highly evolved microbe-host interactions in establishing gut microbiome homeostasis. The appearance of *Bacteroides thetaiotaomicron* in the human gut induces the production of fuc α 1,2Gal β -containing glycans, which serves as a selective carbon substrate for the bacterium [74].

Consumption of Jerusalem artichoke inulin was reported to increase the fecal *Bifidobacterium* level and to cause a small though significant increase in the level of the *Lactobacillus/Enterococcus* group [75]. Besides the *Bifidobacterium*, two groups of butyrate-producing bacteria, namely *Faecalibacterium prausnitzii* and a group of clostridial cluster XIVa bacteria, were found to increase following inulin/fructooligosaccharide (FOS) supplementation in a human intervention study, [26, 76]

During a feeding trial in which each subject consumed a GOS-containing product, the fecal microbiota composition was significantly altered and showed an increase in the abundance of *Bifidobacterium* [77]. The enrichment of *Bifidobacterium* was generally at the expense of *Bacteroides*.

Simple sugars

Digestible carbohydrates are eventually broken down into constituent simple sugars. Adhesion of microbes to the gastrointestinal surface is considered a prerequisite for their colonization and modulation of local and systemic physiological (immunological, hormonal) activities of the host and for competitive exclusion of pathogens [78]. The stereospecific adhesion-receptor interaction involves sugar moieties on the intestinal surface and sugar-binding adhesins on the microbial cell surface [79–81]. Sugars in food may interfere with the adhesion of intestinal microbes, both probiotics and pathogens, to the intestinal surface [82, 83], leading to an altered intestinal microbiota profile.

The *Prevotella* human enterotype is associated with a high intake of carbohydrates and simple sugars, indicating an association with a carbohydrate-based diet typical of agrarian societies [84]. Changes in microbiome composition were detectable within 24 hours of initiating controlled feeding [84]. Self-reported vegans were also found to be in the *Prevotella* enterotype.

Insoluble complex carbohydrates

Plant products are high in slowly digestible and nondigestible carbohydrates. Consumption of 2 apples a day among Japanese resulted in a significant increase in fecal bifidobacteria and clostridia (including the pectinase-positive *C. perfringens*) after a week [85]. The effect was attributed to apple pectin. Similarly, fecal bifidobacteria and lactobacilli were found to increase significantly during the consumption of kiwifruit (2 a day), and the effect was obvious within a day [86]. The effects were, however, temporary, and the microbiota profile returned to that of the baseline upon cessation of consumption [85, 86].

The energy sources that support the microbial community of the large intestine are dietary components that resist degradation in the upper intestinal tract, together with endogenous products such as mucin. Anaerobic metabolism by the microbiome community in the colon produces short-chain fatty acids together with CO₂, H₂ and CH₄ [87]. These fermentation products have significant effects on the gut environment and on the host, as energy sources, regulators of gene expression and cell differentiation and anti-inflammatory agents. Butyrate, for example, is considered to play a particularly important role as an energy source for colonocytes and in the maintenance of gut health [88, 89].

In an animal study and an *in vitro* gastrointestinal tract model, cereal cellulose and insoluble non-starch polysaccharides (NSP) were found to increase *Ruminococcus flavefaciens*-like and *Clostridium*

xylanolyticum-like phylotypes. The cereal amylose content increased the abundance of *Clostridium butyricum*-like phylotypes, whereas the amylopectin and starch contents increased the abundance of *Clostridium ramosum*-like phylotypes, members of *Clostridium* cluster XIVa and *Bacteroides*-like bacteria [90–93].

In a human study, the abundance of *Ruminococcus bromii* and *Eubacterium rectale*/*Roseburia* groups showed significant responses to nondigestible carbohydrates [25]. In a separate study, decreasing nondigestible carbohydrate intake significantly decreased both the detectable numbers of the *E. rectale*/*Roseburia* group and butyrate production [94]. This strong positive correlation between numbers of the *E. rectale*/*Roseburia* group, butyrate detection and nondigestible carbohydrate intake is supported by other human studies [95] and *in vitro* studies [96].

It was reported that a Japanese diet containing a high level of dietary fiber led to lower counts of anaerobic bacteria such as *Clostridium*, *Bacteroides* and *Bacillus subtilis*, and higher counts in *Bifidobacterium* and *Fusobacterium* [97, 98]. A slightly different observation was reported by Finegold et al. [99] in a study comparing the Japanese diet (containing soybean, radishes, cabbage, fish, seaweed and green tea) and Western diet (high in meat); they concluded that the Japanese diet resulted in an intestinal microflora with lower counts of *Bacteroides*, particularly *B. fragilis*; higher counts of some facultative or aerobic organisms such as *Lactobacillus*, *E. coli*, *Proteus*, *Klebsiella*, *Staphylococcus*, *Streptococci* and *Clostridium*; some Gram-positive anaerobic bacilli such as *Eubacterium*; and some *Ruminococcus* species.

The African diet consists mainly of cereal (millet, grain, sorghum), legumes (black-eye peas) and vegetables and is generally high in starch, fiber and non-animal protein. African children showed a significant enrichment in Bacteroidetes and depletion in Firmicutes, with a unique abundance of bacteria from the genus *Prevotella* and *Xylanibacter* [100]. The latter is known to contain a set of bacterial genes for cellulose and xylan hydrolysis that is not found in EU children.

Bacteroides plays an essential role within the distal gut in the degradation of the fiber consumed by the adult host. *Bacteroides* use a series of membrane protein complexes, termed Sus-like systems, to catabolize plant cell wall glycans in our diets [101]. It is hypothesized that by providing HMG, the mother ensures the presence of this group of bacteria in the infant intestine, allowing the smooth transition from milk to solid vegetable foods in the postweaning diet. Plants were the main source of foods for humans during the first 40 over million years of

human history, that is, before they became omnivorous.

The major nondigestible carbohydrate in wheat is arabinoxylan (represents 50% of the dietary fiber); it is selectively degraded in the colon by xylanases and arabinofuranosidases, producing *Bifidobacteria* (*B. animalis* spp *lactis*), *Roseburia* and *Bacteroides-Prevotella* [102].

A consequence of the fermentation of nondigestible carbohydrates in the proximal colon is the production of organic acids and lowering of luminal pH [103]. Assuming that the increased dietary intake in general of an obese individual resulted in a reduced colonic pH, this pH change could be an important factor in the observed community shift, as different microbes have varying optimal pHs for growth and activities. In a 4-week short-term weight loss program, short-term decreases in *Roseburia* and *Bifidobacterium* were observed in response to reduced carbohydrate intake, but no change was observed in *Bacteroides* [94]. The proportion of *Bacteroides* only increased gradually during a 52-week weight loss period. This may imply the involvement of some longer-term physiological mechanism (pH change) rather than a short-term response to diet in the abundance of gut *Bacteroides*.

Fat and fatty acids

Obesity is a major health concern in developed countries. A high-fat (HF) diet in an animal model was found to modulate the dominant intestinal bacterial population; *Bacteroides*-like bacteria were significantly reduce, and so were the *E. rectal*-*C. coccoides* group and *Bifidobacterium* [10, 104]. The polyunsaturated fatty acid component of fat appears to be a determinant factor for the adherence of intestinal bacteria to the mucosal surface and their growth [105]. In animal models, an HF diet induced pro-inflammatory cytokines such as IL-1, IL-6 and TNF- α , favoring hyperinsulinemia and excessive hepatic and adipose tissue lipid storage, leading to metabolic disorder (type 2 diabetes and insulin resistance) [106–110]. The relationship between HF feeding and the development of a low-grade inflammatory tone and metabolic disease have been attributed to reduced numbers of *Bifidobacterium* and a higher plasma endotoxin (Gram-negative bacteria-derived lipopolysacchaide) concentration.

Protein

The quantity and quality of protein constituents in food are clearly different in Western and Eastern diets. In an early study based on culturally dependent methods, consumption of meat among human subjects increased the counts of fecal *Bacteroides*, *Bifidobacterium*,

Peptococcus and anaerobic *Lactobacillus* species [111]. A recent study by Kabeerdoss et al [112] using molecular techniques for comparison of the fecal microbiota of lacto-vegetarian and omnivorous young women showed that *Clostridium* cluster XIVa bacteria (also referred to as the *Clostridium coccoides* group) and butyrate-producing bacteria, specifically *Roseburia-E. rectal*, were significantly more abundant in the fecal microbiota of omnivores [112]. Functional attributes that have been identified for *Clostridium* cluster XIVa species include acetogenesis [113], utilization of aromatic compounds from the diet [114], metabolism of linoleic acid [115] and degradation of mucin [116].

Bacteroides enterotype has been proposed to be associated with a diet high in animal protein, a variety of amino acids and saturated fats [84, 100], which suggests that meat consumption as in a Western diet characterized this enterotype. The high protein and fat enterotype appears to be stable; a 10-day dietary intervention (low-fat, high-fiber diet) did not result in alteration of enterotypes [84]. This, however, casts uncertainty on the direct association of *Bacteroides* and a high animal protein and saturated fat diet. Residual proteins that enter the large intestine are fermented by *Bacteroides* and *Clostridium* [117] into a range of products depending on the amino acid composition. For example, branched-chain amino acids yield branched chain fatty acids, including isobutyrate and isovalerate. In the presence of typical colonic concentrations of SCFAs, growth of human colonic *Bacteroides* was found to be strongly inhibited at a pH of 5.5 (acidic), whereas many Firmicutes, including the most abundant butyrate producers, were less affected. The effect of diet on *Bacteroides* could be pH dependent.

Nonnutritive dietary components

Antibacterial foods such as *Capsicum annuum* (red pepper) and *Allium sativum* (garlic) have been shown to inhibit *Bacillus cereus*, *B. subtilis*, and *C. tetani*, [118] and *Helicobacter pylori* [119].

Our dietary intake of polyphenols ranges between 0.15 and 1 g/day [120]. The predominant polyphenols in foods and beverages are flavonoids, consisting mainly of catechins, proanthocyanidins, anthocyanidins, flavonols and flavones. A significant portion of dietary polyphenols is not absorbed, and those absorbed into the body are metabolized in the liver, excreted through the bile as glucuronides and accumulated in the ileal and colorectal lumen [121].

Phenolic compounds from olives [122], tea [123], wine [124] and berries [125–128] have demonstrated antimicrobial properties. Tea polyphenols have been

shown to inhibit the growth of *Bacteroides*, *Clostridium* (*C. perfringens* and *C. difficile*), *E. coli* and *Salmonella typhimurium* [123]. Wild blueberries (*Vaccinium angustifolium*) have been reported to increase the proportion of *Bifidobacterium* and *Lactobacillus acidophilus* population after 6 weeks of consumption, but showed no effect on *Bacteroides*, *Prevotella*, *Enterococcus* and *C. coccoides* [125, 128].

The effects of polyphenols are related to the chemical structure of the compounds and bacterial species. Caffeic acid generally exerted a more significant inhibitory effect on microbial growth than epicatechin, catechin, 3-O-methylgallic acid and gallic acid [123]. Another *in vitro* study showed that (+)-catechin increased the counts of the *C. coccoides-E. rectale* group and *E. coli*, but inhibited those of *C. histolyticum* [129]. The effects of (–)-epicatechin were less pronounced in increasing the growth of the *C. coccoides-E. rectale* group.

Interestingly, the growth of beneficial bacteria (*Bifidobacterium* and *Lactobacillus*) was relatively unaffected or favored by dietary polyphenols [122, 129]. Resveratrol, a potent antioxidant found in wine, favored the growth of *Bifidobacterium* and *Lactobacillus* [124] and abolished the expression of virulence factors of *Proteus mirabilis* for invasion of human urothelial cells [130]. Anthocyanins from berries have also been proven to inhibit the growth of pathogenic *Staphylococcus*, *Salmonella*, *H. pylori* and *B. cereus* [126, 127]. Phenolics, and flavonoids may also reduce the ability of *L. rhamnosus* to adhere to intestinal epithelial cells [131].

Polyphenols are widely found in plant products (fruits, vegetable, tea leaves). Humans were largely herbivorous for the first 4 million years or so of history. Polyphenol-tolerant and degrading gut microbes must have evolved to be commensal; polyphenols thus serve the function as a gate stopper for microbes (pathogens) that enter the gut occasionally.

STARVATION

Undernourishment in general leads to an abundance of enteric pathogens, such as *Campylobacteraceae* (35-fold more compared with healthy control subjects), *Helicobacteraceae* (12-fold) and *Bacteroidaceae* (4-fold) [132]. On the other hand, *Enterobacteriaceae*, *Shewanellaceae*, *Thermotogaceae*, *Eubacteriaceae*, *Streptococcaceae*, *Methanosarcinaceae* and *Thermoprotei* were reduced by half.

GENERAL CONCLUSION

Diet is clearly a major determining factor of the gut microbiome. The response of the gut microbiota to dietary impact is often rapid; alteration was observed within 24 hours. The enterotype is, however, determined by long-term dietary habits in terms of the proportion and type of carbohydrates, protein and fat. Few nonnutritive dietary components have been studied; polyphenols show potential as moderators of gut microbiome homeostasis. Nonnutritive dietary components should be the focus in future study of the dietary effects on the gut microbiome.

REFERENCES

- Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. 2005. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell* 122: 107–118. [[Medline](#)] [[CrossRef](#)]
- Mazmanian SK, Round JL, Kasper DL. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature* 453: 620–625. [[Medline](#)] [[CrossRef](#)]
- Troy EB, Kasper DL. 2010. Beneficial effects of *Bacteroides fragilis* polysaccharides on the immune system. *Front Biosci* 15: 25–34. [[Medline](#)] [[CrossRef](#)]
- García-Lafuente A, Antolín M, Guarner F, Crespo E, Malagelada JR. 2001. Modulation of colonic barrier function by the composition of the commensal flora in the rat. *Gut* 48: 503–507. [[Medline](#)] [[CrossRef](#)]
- Mital BK, Garg SK. 1995. Anticarcinogenic, hypocholesterolemic, and antagonistic activities of *Lactobacillus acidophilus*. *Crit Rev Microbiol* 21: 175–214. [[Medline](#)] [[CrossRef](#)]
- Miyauchi E, Morita H, Tanabe S. 2009. *Lactobacillus rhamnosus* alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase *in vivo*. *J Dairy Sci* 92: 2400–2408. [[Medline](#)] [[CrossRef](#)]
- Irvine EJ, Marshall JK. 2000. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. *Gastroenterology* 119: 1740–1744. [[Medline](#)] [[CrossRef](#)]
- Vorobjova T, Uibo O, Ojakivi I, Teesalu K, Panarina M, Heilman K, Uibo R. 2011. Lower expression of tight junction protein 1 gene and increased FOXP3 expression in the small bowel mucosa in coeliac disease and associated type 1 diabetes mellitus. *Int Arch Allergy Immunol* 156: 451–461. [[Medline](#)] [[CrossRef](#)]
- Deitch EA. 1990. Bacterial translocation of the gut flora. *J Trauma* 30:(Suppl): S184–S189. [[Medline](#)] [[CrossRef](#)]
- Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. 2007a. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 56: 1761–1772. [[Medline](#)] [[CrossRef](#)]
- Goldin BR, Swenson L, Dwyer J, Sexton M, Gorbach SL. 1980. Effect of diet and *Lactobacillus acidophilus* supplements on human fecal bacterial enzymes. *J Natl Cancer Inst* 64: 255–261. [[Medline](#)]
- Huycke MM, Abrams V, Moore DR. 2002. *Enterococcus faecalis* produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. *Carcinogenesis* 23: 529–536. [[Medline](#)] [[CrossRef](#)]
- Vesterlund S. 2009. Production of antimicrobial substances. In *Handbook of probiotics and Prebiotics*, 2nd ed. Lee YK, Salminen S (eds). Wiley, Hoboken, pp. 391–394.
- Reid G, Burton J. 2002. Use of *Lactobacillus* to prevent infection by pathogenic bacteria. *Microbes Infect* 4: 319–324. [[Medline](#)] [[CrossRef](#)]
- Gibson GR, Wang X. 1994. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. *J Appl Bacteriol* 77: 412–420. [[Medline](#)] [[CrossRef](#)]
- Louis P, Flint HJ. 2009. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol Lett* 294: 1–8. [[Medline](#)] [[CrossRef](#)]
- Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. 2008. The role of butyrate on colonic function. *Aliment Pharmacol Ther* 27: 104–119. [[Medline](#)] [[CrossRef](#)]
- Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. *Science* 308: 1635–1638. [[Medline](#)] [[CrossRef](#)]
- Miller TL, Wolin MJ. 1986. Methanogens in human and animal intestinal tracts. *Sys. Appl Microbiol* 7: 223–229. [[CrossRef](#)]
- Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. 2009. Human gut microbiota in obesity and after gastric bypass. *Proc Natl Acad Sci USA* 106: 2365–2370. [[Medline](#)] [[CrossRef](#)]
- Walker A. 2007. Say hello to our little friends. *Nat Rev Microbiol* 5: 572–573. [[Medline](#)] [[CrossRef](#)]
- Fiedorek SC, Pumphrey CL, Casteel HB. 1990. Breath methane production in children with constipation and encopresis. *J Pediatr Gastroenterol Nutr* 10: 473–477. [[Medline](#)] [[CrossRef](#)]
- Weaver GA, Krause JA, Miller TL, Wolin MJ. 1986. Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. *Gut* 27: 698–704. [[Medline](#)] [[CrossRef](#)]

24. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Munoz-Tamayo R, Paslier DLE, Nalin R, Dore J, Leclerc M. 2009. Towards the human intestinal microbiota phylogenetic core. *Environ Microbiol* 11: 2574–2584. [[Medline](#)] [[CrossRef](#)]
25. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. 2011. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J* 5: 220–230. [[Medline](#)] [[CrossRef](#)]
26. Louis P, Young P, Holtrop G, Flint HJ. 2010. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA transferase gene. *Environ Microbiol* 12: 304–314. [[Medline](#)] [[CrossRef](#)]
27. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464: 59–65. [[Medline](#)] [[CrossRef](#)]
28. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS ONE* 5(2): e9085. [[Medline](#)] [[CrossRef](#)]
29. Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 32: 815–827. [[Medline](#)] [[CrossRef](#)]
30. Fava F, Danese S. 2011. Intestinal microbiota in inflammatory bowel disease: Friend of foe? *World J Gastroenterol* 17: 557–566. [[Medline](#)] [[CrossRef](#)]
31. Rhodes JM. 2007. The role of *Escherichia coli* in inflammatory bowel disease. *Gut* 56: 610–612. [[Medline](#)] [[CrossRef](#)]
32. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Jarnerot G, Engstrand L, Tysk C, Jansson JK. 2009. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. *Inflamm Bowel Dis* 15: 653–660. [[Medline](#)] [[CrossRef](#)]
33. Lim M, Adams JD, Wilcox M, Finan P, Sagar P, Burke D. 2009. An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota. *Dis Colon Rectum* 52: 1492–1500. [[Medline](#)] [[CrossRef](#)]
34. Zella GC, Hait EJ, Glavan T, Gevers D, Ward DV, Kitts CL, Korzenik JR. 2011. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. *Inflamm Bowel Dis* 17: 1092–1100. [[Medline](#)] [[CrossRef](#)]
35. Keighley MR, Arabi Y, Dimock F, Burdon DW, Allan RN, Alexander-Williams J. 1978. Influence of inflammatory bowel disease on intestinal microflora. *Gut* 19: 1099–1104. [[Medline](#)] [[CrossRef](#)]
36. Van de Merwe JP, Schröder AM, Wensink F, Hazenberg MP. 1988. The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. *Scand J Gastroenterol* 23: 1125–1131. [[Medline](#)] [[CrossRef](#)]
37. Bulois P, Desreumaux P, Neut C, Darfeuille-Michaud A, Cortot A, Colombel JF. 1999. Infectious agents and Crohn's disease. *Clin Microbiol Infect* 5: 601–604. [[Medline](#)] [[CrossRef](#)]
38. De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. 2010. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. *BMC Microbiol* 10: 63. [[Medline](#)] [[CrossRef](#)]
39. Schippa S, Iebba V, Barbato M, Di Nardo G, Totino V, Checchi MP, Longhi C, Maiella G, Cucchiara S, Conte MP. 2010. A distinctive 'microbial signature' in celiac pediatric patients. *BMC Microbiol* 10: 175. [[Medline](#)] [[CrossRef](#)]
40. Vaahtovuori J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P. 2008. Fecal microbiota in early rheumatoid arthritis. *J Rheumatol* 35: 1500–1505. [[Medline](#)]
41. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P, Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake DA, Manning P, Kaul A. 2002. Gastrointestinal microflora studies in late-onset autism. *Clin Infect Dis* 35(Suppl 1): S6–S16. [[Medline](#)] [[CrossRef](#)]
42. Parracho HM, Bingham MO, Gibson GR, McCartney AL. 2005. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. *J Med Microbiol* 54: 987–991. [[Medline](#)] [[CrossRef](#)]
43. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR, Green JA 3rd. 2010. Pyrosequencing study of fecal microflora of autistic and control children. *Anaerobe* 16: 444–453. [[Medline](#)] [[CrossRef](#)]
44. Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. 2009. Monitoring bacterial community of human gut microbiota reveals an increase in *Lactobacillus* in

- obese patients and Methanogens in anorexic patients. *PLoS ONE* 4: e7125. [Medline] [CrossRef]
45. Balamurugan R, George G, Kabeerdoss J, Hepsiba J, Chandragunasekaran AMS, Ramakrishna BS. 2010. Quantitative differences in intestinal *Faecalibacterium prausnitzii* in obese Indian children. *Br J Nutr* 103: 335–338. [Medline] [CrossRef]
 46. Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, Flint HJ. 2008. Human colonic microbiota associated with diet, obesity and weight loss. *Int J Obes Lond* 32: 1720–1724. [Medline] [CrossRef]
 47. Kalliomäki M, Collado MC, Salminen S, Isolauri E. 2008. Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr* 87: 534–538. [Medline]
 48. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. 2005. Obesity alters gut microbial ecology. *Proc Natl Acad Sci USA* 102: 11070–11075. [Medline] [CrossRef]
 49. Collado MC, Isolauri E, Laitinen K, Salminen S. 2008. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. *Am J Clin Nutr* 88: 894–899. [Medline]
 50. Tiihonen K, Ouwehand AC, Rautonen N. 2010. Effect of overweight on gastrointestinal microbiology and immunology: correlation with blood biomarkers. *Br J Nutr* 103: 1070–1078. [Medline] [CrossRef]
 51. Onoue M, Kado S, Sakaitani Y, Uchida K, Morotomi M. 1997. Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats. *Cancer Lett* 113: 179–186. [Medline] [CrossRef]
 52. Scanlan PD, Shanahan F, Clune Y, Collins JK, O’Sullivan GC, O’Riordan M, Holmes E, Wang Y, Marchesi JR. 2008. Culture independent analysis of the gut microbiota in colorectal cancer and polyposis. *Environ Microbiol* 10: 789–798. [Medline] [CrossRef]
 53. Sears CL, Pardoll DM. 2011. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. *J Infect Dis* 203: 306–311. [Medline] [CrossRef]
 54. Hirayama K, Rafter J. 2000. The role of probiotic bacteria in cancer prevention. *Microbes Infect* 2: 681–686. [Medline] [CrossRef]
 55. FAO/WHO Joint Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid bacteria. October 2001.
 56. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. 2003. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet* 361: 1869–1871. [Medline] [CrossRef]
 57. Kalliomäki M, Salminen S, Poussa T, Isolauri E. 2007. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. *J Allergy Clin Immunol* 119: 1019–1021. [Medline] [CrossRef]
 58. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 9: 313–323. [Medline] [CrossRef]
 59. Tamboli CP, Caucheteux C, Cortot A, Colombel JF, Desreumaux P. 2003. Probiotics in inflammatory bowel disease: a critical review. *Best Pract Res Clin Gastroenterol* 17: 805–820. [Medline] [CrossRef]
 60. Bixquert Jiménez M. 2009. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? 101: 553-64.
 61. Hayatsu H, Hayatsu T. 1993. Suppressing effect of *Lactobacillus casei* administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. *Cancer Lett* 73: 173–179. [Medline] [CrossRef]
 62. Aso Y, Akazan H. 1992. Prophylactic effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer. BLP Study Group. *Urol Int* 49: 125–129. [Medline] [CrossRef]
 63. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. 1995. Preventive effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. *Eur Urol* 27: 104–109. [Medline]
 64. Spanhaak S, Havenaar R, Schaafsma G. 1998. The effect of consumption of milk fermented by *Lactobacillus casei* strain Shirota on the intestinal microflora and immune parameters in humans. *Eur J Clin Nutr* 52: 899–907. [Medline] [CrossRef]
 65. Fujisawa T, Shinohara K, Kishimoto Y, Terada A. 2006. Effect of miso soup containing natto on the composition and metabolic activity of human fecal flora. *Microb Ecol Health Dis* 18: 79–84. [CrossRef]
 66. Simon GL, Gorbach SL. 1984. Intestinal flora in health and disease. *Gastroenterology* 86: 174–193. [Medline]
 67. Dethlefsen L, Eckburg PB, Bik EM, Relman DA. 2006. Assembly of the human intestinal microbiota. *Trends Ecol Evol* 21: 517–523. [Medline] [CrossRef]
 68. Flint HJ. 2006. The significance of prokaryote diversity in the human gastrointestinal tract. In *Prokaryotic Diversity: Mechanisms and Significance*. Logan NA, Lappin-Scott HM, Oyston PCF (eds). Cambridge, UK: Cambridge University Press, pp. 65–90. SGM Symposium vol. 66.
 69. Ley RE, Peterson DA, Gordon JI. 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 124: 837–848. [Medline] [CrossRef]
 70. Crittenden R, Playne M. 2009. Prebiotics. In *Handbook of probiotics and Prebiotics*, 2nd ed. Lee YK, Salminen S (eds). Wiley, Hoboken. pp. 535–581.
 71. German JB, Freeman SL, Lebrilla CB, Mills DA. 2008. Human milk oligosaccharides: evolution, structures and bioselectivity as substrates for intestinal bacteria.

- Nestle Nutr Workshop Ser Pediatr Program 62: 205–218. [Medline] [CrossRef]
72. Marcobal A, Sonnenburg JL. 2012. Human milk oligosaccharide consumption by intestinal microbiota. *Clin Microbiol Infect* 18:(Suppl 4): 12–15. [Medline] [CrossRef]
 73. Marcobal A, Barboza M, Sonnenburg ED, Pudlo N, Martens EC, Desai P, Lebrilla CB, Weimer BC, Mills DA, German JB, Sonnenburg JL. 2011. *Bacteroides* in the infant gut consume milk oligosaccharides via mucus-utilization pathways. *Cell Host Microbe* 10: 507–514. [Medline] [CrossRef]
 74. Hooper LV, Midtvedt T, Gordon JI. 2002. How host-microbial interactions shape the nutrient environment of the mammalian intestine. *Annu Rev Nutr* 22: 283–307. [Medline] [CrossRef]
 75. Ramnani P, Gaudier E, Bingham M, van Bruggen P, Tuohy KM, Gibson GR. 2010. Prebiotic effect of fruit and vegetable shots containing Jerusalem artichoke inulin: a human intervention study. *Br J Nutr* 104: 233–240. [Medline] [CrossRef]
 76. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. 2009. Effect of inulin on the human gut microbiota: stimulation of *Bifidobacterium adolescentis* and *Faecalibacterium prausnitzii*. *Br J Nutr* 101: 541–550. [Medline] [CrossRef]
 77. Davis LMG, Martínez I, Walter J, Goin C, Hutkins RW. 2011. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. *PLoS ONE* 6: e25200. [Medline] [CrossRef]
 78. Salminen S, Bouley MC, Boutron-Rualt MC, Cummings J, Frank A, Gibson G, Isolauri E, Moreau MC, Roberfroid M, Rowland I. 1998. Functional food science and gastrointestinal physiology and function. *Br J Nutr* 80:(Suppl 1): S147–S171. [Medline] [CrossRef]
 79. Adlerberth I, Ahrne S, Johansson ML, Molin G, Hanson LA, Wold AE. 1996. A manose-specific adherence mechanism in *Lactobacillus plantarum* conferring binding to the human colonic cell line HT-29. *Appl Environ Microbiol* 62: 2244–2251. [Medline]
 80. Ofek I, Beachey EH, Sharon N. 1978. Surface sugars of animal cells as determinants of recognition in bacterial adherence. *Trends Biochem Sci* 3: 159–160. [CrossRef]
 81. Yamamoto K, Miwa T, Taniguchi H, Nagano T, Shimamura K, Tanaka T, Kumagi H. 1996. Binding specificity of *Lactobacillus* to glycolipids. *Biochem Biophys Res Commun* 228: 148–152. [Medline] [CrossRef]
 82. Lee YK, Puong KY. 2002. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. *Br J Nutr* 88:(Suppl 1): S101–S108. [Medline] [CrossRef]
 83. Neeser JR, Granato D, Rouvet M, Servin A, Teneberg S, Karlsson KA. 2000. *Lactobacillus johnsonii* La1 share carbohydrate-binding specificities with several enteropathogenic bacteria. *Glycobiol* 10: 1193–1199. [CrossRef]
 84. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. 2011. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 334: 105–108. [Medline] [CrossRef]
 85. Shinohara K, Ohashi Y, Kawasumi K, Terada A, Fujisawa T. 2010. Effect of apple intake on fecal microbiota and metabolites in humans. *Anaerobe* 16: 510–515. [Medline] [CrossRef]
 86. Lee YK, Low KY, Siah K, Drummond LM, Kok An Gwee KA. 2012. Kiwifruit (*Actinidia deliciosa*) changes intestinal microbial profile. *Microb Ecol Health Dis* 23: 18572–18576.
 87. Macfarlane GT, Gibson GR. 1997. Carbohydrate fermentation, energy transduction and gas metabolism in the human large intestine. In *Gastrointestinal Microbiology*, Vol. 1. Mackie RI, White BA (eds). Chapman and Hall, London. pp. 269–318.
 88. McIntyre A, Gibson PR, Young GP. 1993. Butyrate production from dietary fiber and protection against large bowel cancer in a rat model. *Gut* 34: 386–391. [Medline] [CrossRef]
 89. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. 2002. The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett* 217: 133–139. [Medline] [CrossRef]
 90. Bindelle J, Pieper R, Montoya CA, Van Kessel AG, Leterme P. 2011. Nonstarch polysaccharide-degrading enzymes alter the microbial community and the fermentation patterns of barley cultivars and wheat products in an in vitro model of the porcine gastrointestinal tract. *FEMS Microbiol Ecol* 76: 553–563. [Medline] [CrossRef]
 91. Louis P, Scott KP, Duncan SH, Flint HJ. 2007. Understanding the effects of diet on bacterial metabolism in the large intestine. *J Appl Microbiol* 102: 1197–1208. [Medline] [CrossRef]
 92. Pieper R, Bindelle J, Rossnagel B, Van Kessel A, Pascal Leterme P. 2009. Effect of carbohydrate composition in barley and oat cultivars on microbial ecophysiology and proliferation of *Salmonella enterica* in an in vitro model of the porcine gastrointestinal tract. *Appl Environ Microbiol* 75: 7006–7016. [Medline] [CrossRef]
 93. Topping D. 2007. Cereal complex carbohydrates and their contribution to human health. *J Cereal Sci* 46: 220–229. [CrossRef]
 94. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. 2007. Reduced dietary intake of carbohydrates by obese subjects results in decreased

- concentrations of butyrate and butyrate-producing bacteria in feces. *Appl Environ Microbiol* 73: 1073–1078. [[Medline](#)] [[CrossRef](#)]
95. Abell GCJ, Cooke CM, Bennett CN, Conlon MA, McOrist AL. 2008. Phylotypes related to *Ruminococcus bromii* are abundant in the large bowel of humans and increase in response to a diet high in resistant starch. *FEMS Microbiol Ecol* 66: 505–515. [[Medline](#)] [[CrossRef](#)]
 96. Leitch ECM, Walker AW, Duncan SH, Holtrop G, Flint HJ. 2007. Selective colonization of insoluble substrates by human colonic bacteria. *Environ Microbiol* 72: 667–679. [[CrossRef](#)]
 97. Benno Y, Endo K, Mizutani T, Namba Y, Komori T, Mitsuoka T. 1989. Comparison of fecal microflora of elderly persons in rural and urban areas of Japan. *Appl Environ Microbiol* 55: 1100–1105. [[Medline](#)]
 98. Benno Y, Endo K, Miyoshi H, Okuda T, Koishi H, Mitsuoka T. 1989. Effect of rice fiber on human fecal microflora. *Microbiol Immunol* 33: 435–440. [[Medline](#)]
 99. Finegold SM, Attebery HR, Sutter VL. 1974. Effect of diet on human fecal flora: comparison of Japanese and American diets. *Am J Clin Nutr* 27: 1456–1469. [[Medline](#)]
 100. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. 2010. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci USA* 107: 14691–14696. [[Medline](#)] [[CrossRef](#)]
 101. Martens EC, Lowe EC, Chiang H, Pudlo NA, Wu M, McNulty NP, Abbott DW, Henrissat B, Gilbert HJ, Bolam DN, Gordon JI. 2011. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. *PLoS Biol* 9: e1001221. [[Medline](#)] [[CrossRef](#)]
 102. Neyrinck AM, Sam Possemiers S, Druart C, van de Wiele T, De Backer F, Cani PD, Larondelle Y, Delzenne NM. 2011. Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, roseburia and *Bacteroides/Prevotella* in diet-induced obese mice. *PLoS ONE* 6: e20944. [[Medline](#)] [[CrossRef](#)]
 103. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. 1974. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. *Gut* 15: 999–1004. [[Medline](#)] [[CrossRef](#)]
 104. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. 2007b. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. *Diabetologia* 50: 2374–2383. [[Medline](#)] [[CrossRef](#)]
 105. Kankaanpää PE, Salminen SJ, Isolauri E, Lee YK. 2001. The influence of polyunsaturated fatty acids on probiotic growth and adhesion. *FEMS Microbiol Lett* 194: 149–153.
 106. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α - and obesity induced insulin resistance. *Science* 271: 665–668. [[Medline](#)] [[CrossRef](#)]
 107. Kahn BB, Flier JS. 2000. Obesity and insulin resistance. *J Clin Invest* 106: 473–481. [[Medline](#)] [[CrossRef](#)]
 108. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. 2005. Tumor necrosis factor- α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. *Diabetes* 54: 2939–2945. [[Medline](#)] [[CrossRef](#)]
 109. Wellen KE, Hotamisligil GS. 2005. Inflammation, stress, and diabetes. *J Clin Invest* 115: 1111–1119. [[Medline](#)]
 110. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* 112: 1796–1808. [[Medline](#)]
 111. Reddy BS, Weisburger JH, Wynder EL. 1975. Effects of high risk and low risk diets for colon carcinogenesis on fecal microflora and steroids in man. *J Nutr* 105: 878–884. [[Medline](#)]
 112. Kabeerdoss J, Devi RS, Mary RR, Ramakrishna BS. 2012. Faecal microbiota composition in vegetarians: comparison with omnivores in a cohort of young women in southern India. *Br J Nutr* 108: 953–957. [[Medline](#)]
 113. Bernalier A, Lelait M, Rochet V, Grivet JP, Gibson GR, Durand M. 1996. Acetogenesis from H₂ and CO₂ by methane and non-methane-producing human colonic bacterial communities. *FEMS Microbiol Ecol* 19: 193–202. [[CrossRef](#)]
 114. Simmering R, Pforte H, Jacobasch G, Blaut M. 2002. The growth of the flavonoid-degrading intestinal bacterium, *Eubacterium ramulus*, is stimulated by dietary flavonoids in vivo. *FEMS Microbiol Ecol* 40: 243–248. [[Medline](#)] [[CrossRef](#)]
 115. Devillard E, McIntosh FM, Duncan SH, Wallace RJ. 2007. Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid. *J Bacteriol* 189: 2566–2570. [[Medline](#)] [[CrossRef](#)]
 116. Hoskins LC. 1993. Mucin degradation in the human gastrointestinal tract and its significance to enteric microbial ecology. *Eur J Gastroenterol Hepatol* 5: 205–213. [[CrossRef](#)]
 117. Macfarlane GT, Gibson GR, Cummings JH. 1992. Comparison of fermentation reactions in different regions of the human colon. *J Appl Bacteriol* 72: 57–64. [[Medline](#)]
 118. Cichewicz RH, Thorpe PA. 1996. The antimicrobial properties of chile peppers (*Capsicum* species) and their uses in Mayan medicine. *J Ethnopharmacol* 52:

- 61–70. [\[Medline\]](#) [\[CrossRef\]](#)
119. Sivam GP, Lampe JW, Ulness B, Swanzy SR, Potter JD. 1997. *Helicobacter pylori*-in vitro susceptibility to garlic (*Allium sativum*) extract. *Nutr Cancer* 27: 118–121. [\[Medline\]](#) [\[CrossRef\]](#)
120. Scalbert A, Williamson G. 2000. Dietary intake and bioavailability of polyphenols. *J Nutr* 130: 2073S–2085S. [\[Medline\]](#)
121. Bazzocco S, Mattila I, Guyot S, Renard CM, Aura AM. 2008. Factors affecting the conversion of apple polyphenols to phenolic acids and fruit matrix to short-chain fatty acids by human faecal microbiota in vitro. *Eur J Nutr* 47: 442–452. [\[Medline\]](#) [\[CrossRef\]](#)
122. Medina E, Garcia A, Romero C, de Castro A, Brenes M. 2009. Study of the anti-lactic acid bacteria compounds in table olives. *Int J Food Sci Technol* 7: 1286–1291. [\[CrossRef\]](#)
123. Lee HC, Jenner AM, Low CS, Lee YK. 2006. Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. *Res Microbiol* 157: 876–884. [\[Medline\]](#) [\[CrossRef\]](#)
124. Larrosa M, Yanéz-Gascón MJ, Selma MV, González-Sarrías A, Toti S, Cerón JJ, Tomás-Barberán F, Dolaro P, Espin JC. 2009. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. *J Agric Food Chem* 57: 2211–2220. [\[Medline\]](#) [\[CrossRef\]](#)
125. Molan AL, Lila AA, Mawson J, De S. 2009. In vitro and in vivo evaluation of the prebiotic activity of water-soluble blueberry extracts. *World J Microbiol Biotechnol* 25: 1243–1249. [\[CrossRef\]](#)
126. Nohynek LJ, Alakomi HL, Kahkonen MP, Heinonen M, Helander IM, Oksman-Caldentey KM, Puupponen-Pimiä RH. 2006. Berry phenolics: antimicrobial properties and mechanisms of action against severe human pathogens. *Nutr Cancer* 54: 18–32. [\[Medline\]](#) [\[CrossRef\]](#)
127. Puupponen-Pimiä R, Nohynek L, Hartmann-Schmidlin S, Kähkönen M, Heinonen M, Määttä-Riihinen K, Oksman-Caldentey KM. 2005. Berry phenolics selectively inhibit the growth of intestinal pathogens. *J Appl Microbiol* 98: 991–1000. [\[Medline\]](#) [\[CrossRef\]](#)
128. Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M. 2011. Six-week consumption of a wild blueberry powder drink increases bifidobacteria in the human gut. *J Agric Food Chem* 59: 12815–12820. [\[Medline\]](#) [\[CrossRef\]](#)
129. Tzounis X, Vulevic J, Kuhnle GG, George T, Leonczak J, Gibson GR, Kwik-Urbe C, Spencer JP. 2008. Flavanol monomer-induced changes to the human faecal microflora. *Br J Nutr* 99: 782–792. [\[Medline\]](#)
130. Wang WB, Lai HC, Hsueh PR, Chiou RYY, Lin SB, Liaw SJ. 2006. Inhibition of swarming and virulence factor expression in *Proteus mirabilis* by resveratrol. *J Med Microbiol* 55: 1313–1321. [\[Medline\]](#) [\[CrossRef\]](#)
131. Parkar SG, Stevenson DE, Skinner MA. 2008. The potential influence of fruit polyphenols on colonic microflora and human gut health. *Int J Food Microbiol* 124: 295–298. [\[Medline\]](#) [\[CrossRef\]](#)
132. Gupta SS, Mohammed MH, Ghosh TS, Kanungo S, Nair GB, Mande SS. 2011. Metagenome of the gut of a malnourished child. *Gut Pathog* 3: 7–15. [\[Medline\]](#) [\[CrossRef\]](#)